Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9651983 | 1.00 | USP2 (0.45) | USP2TSHRMAPTABCC4ALDH1A1 | |
| SCHEMBL5597723 | 1.00 | USP2 (0.45) | USP2TSHRMAPTABCC4ALDH1A1 | |
| SCHEMBL9651791 | 0.83 | LMNA (0.38) | MAPTCYP3A4LMNA | |
| SCHEMBL8400134 | 0.80 | — | — | |
| SCHEMBL8400133 | 0.80 | — | — | |
| SCHEMBL8400138 | 0.80 | — | — | |
| SCHEMBL3121647 | 0.79 | LMNA (0.50) | USP2TSHRMAPTABCC4ALDH1A1 | |
| SCHEMBL9453313 | 0.79 | USP2 (0.46) | USP2TSHRMAPTABCC4ALDH1A1 | |
| SCHEMBL20434779 | 0.79 | USP2 (0.46) | USP2TSHRMAPTABCC4ALDH1A1 | |
| SCHEMBL16803184 | 0.79 | USP2 (0.46) | USP2TSHRMAPTABCC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265249-B2 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060189830-A1 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189830-A1 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | ALDH3A1, ALDH1A1, POLL | USP2 4391/4885TSHR 3052/4885MAPT 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.